PIK3CA Mutations
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2026
2027
2028
2029
Cogent BiosciencesCGT6297
Clinical Trials (1)
Total enrollment: 90 patients across 1 trials
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Start: Feb 2026Est. completion: Aug 202990 patients
Phase 1Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space